Dyne Therapeutics (DYN) Operating Income (2019 - 2026)

Dyne Therapeutics' Operating Income history runs 8 years deep, the most recent figure standing at -$125.3 million for Q1 2026.

• In Q1 2026, Operating Income fell 2.37% year-over-year to -$125.3 million; the TTM figure through Mar 2026 stood at -$471.1 million (down 18.66% YoY), while the FY2025 annual figure was -$468.2 million, down 36.15% from the prior year.
• Operating Income was -$125.3 million for Q1 2026 at Dyne Therapeutics, down from -$116.1 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$35.8 million in Q1 2022 to a low of -$125.3 million in Q1 2026.
• Historically, Operating Income has averaged -$79.4 million across 5 years, with a median of -$69.2 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Operating Income grew 22.74% in 2022, then slumped 76.95% in 2025.
• A 5-year view of Operating Income shows it stood at -$40.1 million in 2022, then sank by 68.61% to -$67.7 million in 2023, then tumbled by 43.46% to -$97.1 million in 2024, then slipped by 19.59% to -$116.1 million in 2025, then dropped by 7.88% to -$125.3 million in 2026.
• The last three Operating Income figures came in at -$125.3 million (Q1 2026), -$116.1 million (Q4 2025), and -$113.9 million (Q3 2025), per Business Quant data.